Jennifer Helen Martin is an Australian clinical pharmacologist, physician and academic. She is chair of Clinical Pharmacology in the University of Newcastle School of Medicine and Public Health,[1] Director of the NHMRC funded Australian Centre for Cannabinoid Clinical and Research Excellence (ACRE),[1] and an elected a Fellow of the Australian Academy of Health and Medical Sciences.[2] Martin translates research into practice and policy. Her research involves the investigation of therapeutic drugs, from drug design and development, to clinical trials and studies to investigate how new drugs perform in the general population.

Early life

Martin grew up in Wellington, New Zealand where she followed an early interest in medicine from her love of sport, hoping to one day be the doctor who travelled with the New Zealand Olympic team.[1]

After studying medicine at the University of Otago, moved to work and study in the United Kingdom in 1993, later returning to New Zealand to train as a specialist in pharmacology and internal medicine. Martin moved to Melbourne to undertake a PhD in Medicine in 2000.

Career

Martin was a Rhodes Scholar who has studied politics and health economics at the University of Oxford. She completed a Bachelor of Medicine and Surgery from the University of Otago[1] and a Doctor of Philosophy at Monash University in 2005, examining innate immunity and heart failure pathophysiology in people with type 2 diabetes.[3] Her post-doctoral work investigated macrophage function in high fat diet at the Walter and Eliza Hall Institute.

Following her post-doctoral studies, Martin became the Head of Southside Clinical School at the University of Queensland where she was involved in revising the medical curricula to broaden medical student experiences in healthcare. Martin took on the leadership position of Chair of Clinical Pharmacology at the University of Newcastle in 2013.[1]

Martin was elected a Fellow of the Australian Academy of Health and Medical Sciences in 2020.[2] In the same year she published a report of clinical trials in Australia of using increasingly legal medicines based on cannabis. The report gave advice on ethics and keeping patients safe.[4]

References

  1. 1 2 3 4 5 "Staff Profile". www.newcastle.edu.au. 16 January 2015. Retrieved 12 October 2021.
  2. 1 2 "Academy elects 28 new Fellows". AAHMS - Australian Academy of Health and Medical Sciences. 14 October 2020. Retrieved 12 October 2021.
  3. ↑ "The pathophysiology of heart failure in type 2 diabetes". monash.hosted.exlibrisgroup.com. Retrieved 12 October 2021.
  4. ↑ Martin, Jennifer H.; Hill, Courtney; Walsh, Anna; Efron, Daryl; Taylor, Kaitlyn; Kennedy, Michael; Galettis, Rachel; Lightfoot, Paul; Hanson, Julie; Irving, Helen; Agar, Meera (17 November 2020). "Clinical trials with cannabis medicines—guidance for ethics committees, governance officers and researchers to streamline ethics applications and ensuring patient safety: considerations from the Australian experience". Trials. 21 (1): 932. doi:10.1186/s13063-020-04862-6. ISSN 1745-6215. PMC 7673085. PMID 33203469.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.